Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
DuPont And Caribou Cross-License CRISPR
by Michael McCoy
October 12, 2015
| A version of this story appeared in
Volume 93, Issue 40
DuPont and the biotech firm Caribou Biosciences have agreed to cross-license their intellectual property related to the new gene-editing tool called CRISPR/Cas. Caribou was founded in 2011 by CRISPR research pioneer Jennifer Doudna of the University of California, Berkeley, and colleagues. DuPont obtained its technology in June through a license from Vilnius University. DuPont made an equity investment in Caribou as part of the biotech firm’s recent Series A funding round. The two firms also will collaborate on research.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter